Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Canada Updates Biosimilar Guidance On Reference Drug, Extrapolation, Scientific Advice

This article was originally published in SRA

Executive Summary

Companies wishing to comment on Canada's new draft guideline on biosimilar medicines have four weeks to do so before the consultation period closes on Feb. 151. The guideline, which updates the existing guidance, includes new information in areas like extrapolation and the choice of comparator drug, as well as a section on a biosimilar scientific advice pilot that began in September last year2.

Advertisement
Advertisement
UsernamePublicRestriction

Register